Recipharm announces commercial manufacturing to support Talicia[®] Q1/2020 Launch following U.S. FDA approval
Recipharm, the contract development and manufacturing organisation (CDMO), announced today ongoing large-scale commercial manufacturing of RedHill Biopharma’s (Nasdaq: RDHL) drug, Talicia[® ](omeprazole magnesium, amoxicillin and rifabutin) delayed-release capsules 10 mg[1]/250 mg/12.5 mg, for its planned launch in the first quarter 2020. RedHill and Recipharm have been working in partnership since 2015 to develop and manufacture the product, which is the first rifabutin-based therapy approved treatment for the treatment of Helicobacter pylori infection. Throughout the development